Probiotics for paediatric functional abdominal pain disorders: A rapid review

Fang Chao Linda Ding, Mohammad Karkhaneh, Liliane Zorzela, Hsing Jou, Sunita Vohra, Fang Chao Linda Ding, Mohammad Karkhaneh, Liliane Zorzela, Hsing Jou, Sunita Vohra

Abstract

Background: Functional abdominal pain disorders (FAPD) are prevalent in the paediatric population, however, there is currently no consensus regarding best practices for treatment. The use of probiotics is becoming popular to treat FAPD. The goal of this rapid review is to synthesize the best evidence on the use of probiotics in children with FAPD.

Methods: Searches were conducted on five main databases. Randomized controlled trials (RCTs) of probiotic use in children (0 to 18 years) with FAPD were searched. Populations of interest were patients with functional abdominal pain (FAP), irritable bowel syndrome (IBS), and functional dyspepsia (FD), recruited based on Rome criteria. Outcomes of interest were changes in abdominal pain severity, frequency, and duration.

Findings: Eleven RCTs with 829 participants with the diagnosis of FAP (n=400), IBS (n=329), FD (n=45), and mixed population (n=55) were included. Of six studies of children with FAP, two (n=103) used Lactobacillus rhamnosus GG (LGG) and reported no significant effects on pain, and four (n=281) used Lactobacillus (L) reuteri DSM 17938, of which three (n=229) reported significant positive effects on either severity or frequency of pain. Of six trials of children with IBS, four (n=219) used LGG, of which three (n=168) reported a positive effect. One (n=48) used bifidobacteria and one used VSL #3 (n=59), both demonstrating positive effects with probiotics. Two studies of FD reported no benefit. No adverse events were attributed to probiotics.

Conclusions: There is preliminary evidence for use of probiotics, particularly LGG, in reducing abdominal pain in children with IBS. There are inconsistent positive effects of other probiotics, including L. reuteri DSM 17938, in reducing pain in patients with FAP, IBS, or FD. More RCTs with rigorous methodology using single or combination probiotics are warranted.

Keywords: Abdominal pain; Paediatrics; Probiotics; Review.

Figures

Figure 1.
Figure 1.
Assessment of risk of bias in the studies of probiotics in functional abdominal pain disorder*. *Adopted RevMan software by Cochrane Collaboration (http://community.cochrane.org/tools/review-production-tools/revman-5)
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6735714/bin/pxz036f0002.jpg

References

    1. Assa A, Ish-Tov A, Rinawi F, Shamir R. School attendance in children with functional abdominal pain and inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 2015;61(5):553–7.
    1. Youssef NN, Murphy TG, Langseder AL, Rosh JR. Quality of life for children with functional abdominal pain: A comparison study of patients’ and parents’ perceptions. Pediatrics 2006;117(1):54–9.
    1. Dhroove G, Chogle A, Saps M. A million-dollar work-up for abdominal pain: Is it worth it? J Pediatr Gastroenterol Nutr 2010;51(5):579–83.
    1. Rasquin A, Di Lorenzo C, Forbes D, et al. . Childhood functional gastrointestinal disorders: Child/adolescent. Gastroenterology 2006;130(5):1527–37.
    1. Collins BS, Thomas DW. Chronic abdominal pain. Pediatr Rev 2007;28(9):323–31.
    1. Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016;150(6):1262–79.e2.
    1. Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in western countries: A systematic review. Am J Gastroenterol 2005;100(8):1868–75.
    1. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: A meta-analysis. PLoS One 2015;10(5):e0126982.
    1. Saulnier DM, Riehle K, Mistretta TA, et al. . Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141(5):1782–91.
    1. Korterink JJ, Rutten JM, Venmans L, Benninga MA, Tabbers MM. Pharmacologic treatment in pediatric functional abdominal pain disorders: A systematic review. J Pediatr 2015;166(2):424–31.e6.
    1. Korterink J, Devanarayana NM, Rajindrajith S, Vlieger A, Benninga MA. Childhood functional abdominal pain: Mechanisms and management. Nat Rev Gastroenterol Hepatol 2015;12(3):159–71.
    1. National Institutes of Health. Complementary, Alternative, or Integrative Health: Probiotics: In Depth?2016. <>. Accessed December 2017.
    1. Barnes D, Yeh AM. Bugs and guts: Practical applications of probiotics for gastrointestinal disorders in children. Nutr Clin Pract 2015;30(6):747–59.
    1. Carlson AL, Xia K, Azcarate-Peril MA, et al. . Infant gut microbiome associated with cognitive development. Biol Psychiatry 2018;83(2):148–59.
    1. Slyepchenko A, Carvalho AF, Cha DS, Kasper S, McIntyre RS. Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS Neurol Disord Drug Targets 2014;13(10):1770–86.
    1. Tillisch K. The effects of gut microbiota on CNS function in humans. Gut Microbes 2014;5(3):404–10.
    1. Chen CC, Walker WA. Clinical applications of probiotics in gastrointestinal disorders in children. Natl Med J India 2011;24(3):153–60.
    1. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012;18(30):4012–8.
    1. Giannetti E, Maglione M, Alessandrella A, et al. . A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome: A multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol 2017;51(1):e5–e10.
    1. Jadrešin O, Hojsak I, Mišak Z, et al. . Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children: RCT study. J Pediatr Gastroenterol Nutr 2017;64(6):925–9.
    1. Maragkoudaki M, Chouliaras G, Orel R, Horvath A, Szajewska H, Papadopoulou A. Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr 2017;106(11):1857–62.
    1. Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: A randomized, double-blind, placebo-controlled trial. J Pediatr 2016;174:160–164.e1.
    1. Eftekhari K, Vahedi Z, Kamali Aghdam M, Noemi Diaz D. A randomized double-blind placebo-controlled trial of Lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr 2015;25(6):e2616.
    1. Kianifar H, Jafari SA, Kiani M, et al. . Probiotic for irritable bowel syndrome in pediatric patients: A randomized controlled clinical trial. Electron Physician 2015;7(5):1255–60.
    1. Romano C, Ferrau’ V, Cavataio F, et al. . Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014;50(10):E68–71.
    1. Francavilla R, Miniello V, Magistà AM, et al. . A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010;126(6):e1445–52.
    1. Guandalini S, Magazzù G, Chiaro A, et al. . VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;51(1):24–30.
    1. Gawrońska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25(2):177–84.
    1. Bauserman M, Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial. J Pediatr 2005;147(2):197–201.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009;151(4):264–9, W64.
    1. Guandalini S. The potential for use of probiotics in pediatric irritable bowel syndrome and inflammatory bowel disease. Current Pediatrics Reports 2014;2(3):235.
    1. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf 2014;13(2):227–39.
    1. Salminen MK, Tynkkynen S, Rautelin H, et al. . Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in finland. Clin Infect Dis 2002;35(10):1155–60.
    1. Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis 2016;34(3):260–8.
    1. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011;33(12):1302–10.
    1. Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: A systematic review and meta-analysis. Acta Paediatr 2014;103(4):365–72.
    1. Rutten JM, Korterink JJ, Venmans LM, Benninga MA, Tabbers MM. Nonpharmacologic treatment of functional abdominal pain disorders: A systematic review. Pediatrics 2015;135(3):522–35.
    1. Newlove-Delgado TV, Martin AE, Abbott RA, et al. . Dietary interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017;3:CD010972.
    1. Huertas-Ceballos AA, Logan S, Bennett C, et al. . Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2009;1:Cd003019.
    1. Wegh CA, Benninga MA, Tabbers MM. Effectiveness of probiotics in children with functional abdominal pain disorders and functional constipation: A systematic review. J Clin Gastroenterol 2018;52(1):S10–26.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel